Mekinist (Trametinib) 2mg Tablets | MEK Inhibitor | Novartis Switzerland | GLT

Mekinist is the originator brand of trametinib, the first-in-class oral MEK inhibitor discovered and marketed by Novartis. This listing supplies the Swiss-market presentation in 2 mg film-coated tablets. Switzerland is Novartis's home market, and the product distributed there is manufactured under the same global quality system that supports its approvals by the U.S. FDA, the European Medicines Agency and Swissmedic.

Generic Information: Mekinist (Trametinib)

Trametinib belongs to a class of medicines called MEK inhibitors. MEK1 and MEK2 are enzymes that sit directly downstream of BRAF in the MAPK signaling cascade, the pathway that is abnormally switched on in many melanomas and other cancers. Mekinist blocks both MEK1 and MEK2, and is most commonly prescribed together with the BRAF inhibitor dabrafenib.

What Is Mekinist (Trametinib) Used For?

Mekinist is approved for adults whose tumors carry a BRAF V600 mutation. Its main indications are unresectable or metastatic melanoma, adjuvant treatment of melanoma after surgical removal (with dabrafenib), and — again with dabrafenib — metastatic non-small cell lung cancer and anaplastic thyroid cancer with a BRAF V600E mutation.

How Does Mekinist Work?

In BRAF-mutant tumors the MAPK pathway is permanently active, driving cancer cells to grow and survive. Trametinib binds MEK1 and MEK2 allosterically and silences them, interrupting that growth signal downstream of the mutated BRAF. Adding dabrafenib blocks the pathway at two separate points, which deepens and prolongs the response and helps delay the emergence of resistance.

Indications

• Unresectable or metastatic melanoma with BRAF V600E or V600K mutation
• Adjuvant melanoma therapy with dabrafenib after resection
• Metastatic NSCLC with BRAF V600E mutation, with dabrafenib
• Anaplastic thyroid cancer with BRAF V600E mutation, with dabrafenib

Dosage & Administration

The standard dose is 2 mg once daily, taken at the same time each day with or without food. When combined with dabrafenib, Mekinist is taken once daily while dabrafenib is taken twice daily. Tablets are swallowed whole. The oncologist may reduce the dose or hold treatment if side effects arise.

Side Effects

Rash, diarrhea, fatigue, nausea, swelling of the limbs and fever are the most common effects. More serious risks include reduced heart function (cardiomyopathy), blood clots, severe skin reactions, eye problems such as retinal vein occlusion, lung inflammation, and bleeding. Heart function and skin and eye symptoms are monitored during therapy.

Storage & Handling

Keep tablets at room temperature in the original container, away from moisture and light, and out of children's reach. Do not use past the expiry date.

Why Choose the GLT?

• Swiss-sourced originator — Mekinist from Novartis's home market.
• First-in-class MEK inhibitor — the reference partner for dabrafenib.
• Traceable supply — batch documentation provided.

How to Order Mekinist (Switzerland) from GLT

1. Contact GLT via WhatsApp +86 15234153837 or email [email protected] with quantity and destination.
2. Receive a quotation and delivery estimate.
3. Pay through Hao Yi Lian / 好易联.
4. Goods ship with documentation and tracking.

A valid prescription may be requested before dispatch. Institutions and individual patients are both served.

FAQ

1. Where is this Mekinist sourced from?

This Mekinist is sourced from the Swiss market and is the authentic Novartis originator product.

2. What strength is supplied?

This listing is for 2 mg film-coated tablets.

3. Do I need a prescription?

Yes, trametinib is prescription-only, and a prescription may be requested before dispatch.